Pamplona, Spain – December 24, 2024– Telum Therapeutics, a leading biotechnology company specializing in drug discovery, is pleased to announce the filing of a new patent, with a priority date of December 24, 2024, titled “Antimicrobial Peptides.” This patent represents a significant step forward in the fight against antibiotic-resistant bacteria and underscores Telum’s commitment to developing innovative antimicrobial solutions.
The invention relates to the field of clinical and veterinary microbiology and describes a novel polypeptide with potent antibacterial properties. This new antimicrobial peptide is particularly effective against antibiotic-resistant Gram-negative bacteria, offering a promising alternative to traditional antibiotics. Additionally, the peptide minimizes the emergence of new resistances, addressing one of the most pressing challenges in modern medicine.
“The filing of this new patent marks another milestone in Telum Therapeutics’ mission to combat antibiotic resistance with cutting-edge biotechnological solutions,” said Dr. Subhendu Basu, CEO of Telum. “This antimicrobial peptide family represents a powerful new tool in our fight
against multidrug-resistant infections, reinforcing our position as innovators in antimicrobial therapy.”
Telum Therapeutics specializes in developing engineered peptides and phage-derived lysins as next-generation antimicrobial agents. By harnessing the natural antibacterial activity of these molecules, Telum is pioneering novel approaches to infection treatment that circumvent traditional resistance mechanisms.
For more information about Telum Therapeutics and its recent developments, please visit https://telumtherapeutics.com/our-science/pipeline/.